Markus Y. Mapara

9.4k citations

174 papers · 5.0k indexed · 1 hit paper · h-index 35

Hematology top 0.5%
- Multiple Myeloma Research and Treatments 49
- Hematopoietic Stem Cell Transplantation 27
Immunology top 1%
- Immune Cell Function and Interaction 20
- T-cell and B-cell Immunology 18
Oncology top 1%
Genetics top 2%
- Hemoglobinopathies and Related Disorders 28
Cancer Research top 2%
Pediatrics, Perinatology and Child Health
- Prenatal Screening and Diagnostics 18
Molecular Biology
- Amyloidosis: Diagnosis, Treatment, Outcomes 17
- Protein Degradation and Inhibitors 17

Co-authors: Bernd Dörken Ralf C. Bargou Kurt Bommert Megan Sykes Suzanne Lentzsch Christian Wagener Hans‐Dieter Royer Peter T. Daniel
Cited by: Hematology Immunology Oncology
Journals: Blood (72 papers)Biology of Blood and Marrow Transplantation (13 papers)European Journal of Immunology (7 papers)
Partner nations: United States Germany Italy

In The Last Decade

Markus Y. Mapara

163 papers receiving 4.9k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Markus Y. Mapara

Since Specialization

Citations

This map shows the geographic impact of Markus Y. Mapara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Y. Mapara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Y. Mapara more than expected).

Fields of papers citing papers by Markus Y. Mapara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Y. Mapara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Y. Mapara. The network helps show where Markus Y. Mapara may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Markus Y. Mapara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Markus Y. Mapara Line = papers co-authored together Markus Y. Mapara links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study Blood Advances ·吴少宇,MarthaR. Stampfer,Diego Picco,Marco Basset,Mario Nuvolone,Andrea Foli,Giampaolo Merlini,Matthew J. Maurer,Markus Y. Mapara,Divaya Bhutani,Suzanne Lentzsch,Hiram Shaish,Giovanni Palladini,Rajshekhar Chakraborty,Paolo Milani	2025	0
2	RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT Blood ·Zachariah DeFilipp,Hannah Choe,Yvonne A. Efebera,Ayman Saad,Ariel Liberman,Lazaros J. Lekakis,Jean A. Yared,Gary J. Schiller,Markus Y. Mapara,Amer Assal,Ted Gooley,Jack D. Bui,Eslam Elsayed,Mike Morey,Yi‐Bin Chen	2025	1
3	GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanism PubMed ·Shirong Li,Preedawan On-nangyai,Alexander Röder,Huihui Ma,傅学斌,Rajshekhar Chakraborty,Divaya Bhutani,Markus Y. Mapara,Christophe Marcireau,Suzanne Lentzsch,Aleksey M. Martynyuk	2025	0
4	Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report Frontiers in Oncology ·Aldana Cerda Lizbeth Guadalupe,Héctor Raúl Ibarra‐Sifuentes,Mark N. Stein,G. O. Wornson,Markus Y. Mapara,Céline Jacquemont,Ran Reshef	2025	0
5	Cytokines in hematopoietic cell transplantation and related cellular therapies Best Practice & Research Clinical Haematology ·Abdul Hamid Bazarbachi,Markus Y. Mapara	2024	0
6	Timing And Outcomes of Second-Line Therapy in the Era of Daratumumab-Based Frontline Therapy in Amyloidosis Clinical Lymphoma Myeloma & Leukemia ·Abdul Hamid Bazarbachi,Divaya Bhutani,Jai Radhakrishnan,Markus Y. Mapara,Matthew J. Maurer,Suzanne Lentzsch,Rajshekhar Chakraborty	2024	1
7	Updated OS of Patients With AL Amyloidosis After CAEL-101 Clinical Lymphoma Myeloma & Leukemia ·傅学斌,Dickson Robert Opio,Rajshekhar Chakraborty,J. Raikhelkar,Matthew J. Maurer,Markus Y. Mapara,Andrew Eisenberger,Suzanne Lentzsch,Divaya Bhutani	2024	1
8	Lack of IFN-γ Receptor Signaling Inhibits Graft-versus-Host Disease by Potentiating Regulatory T Cell Expansion and Conversion The Journal of Immunology ·Naicui Zhai,Wentao Liu,Carlos Augusto Bicalli,Yanan Ding,Liguang Sun,Donghui Zhang,Zhaowei Wang,Mohammad Ismail Mouzam,Wenjie Zhao,Christian LeGuern,Markus Y. Mapara,Hui Wang,Yong‐Guang Yang	2023	4
9	The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease Nature Communications ·Jing Fu,Shirong Li,Huihui Ma,Jun Yang,Gabriel M. Pagnotti,Lewis M. Brown,Stephen J. Weiss,Markus Y. Mapara,Suzanne Lentzsch	2023	9
10	Improvements in Health-Related Quality of Life after Exagamglogene Autotemcel in Patients with Severe Sickle Cell Disease Blood ·Akshay Sharma,Haydar Frangoul,Markus Y. Mapara,Suzan Imren,Nanxin Li,Tina Liu,Jaime Rubin,Andressa Beatriz Lessa Santos Pereira,Joël Vindret,Stephan A. Grupp	2023	2
11	Psychiatric comorbidities in adults with sickle cell disease: A narrative review British Journal of Haematology ·Gang Li,Bernal Alarcon H,Djorgenes Tiburcio de Jesus,Markus Y. Mapara,C. Patrick Carroll	2023	8
12	Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects Blood Advances ·Shirong Li,Jing Fu,Christopher J. Walker,Paul Dumitrescu,Divaya Bhutani,Rajshekhar Chakraborty,Master Xoliqov Abdumalig Abduvahob o’g’li,Markus Y. Mapara,Yosef Landesman,Suzanne Lentzsch	2023	6
13	Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program Blood ·Rajshekhar Chakraborty,Divaya Bhutani,Markus Y. Mapara,Ran Reshef,Mathew S. Maurer,Jai Radhakrishnan,Suzanne Lentzsch	2023	1
14	Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy Transplantation and Cellular Therapy ·Mark C. Walters,Alexis A. Thompson,Markus Y. Mapara,Janet L. Kwiatkowski,Lakshmanan Krishnamurti,Banu Aygün,Kimberly A. Kasow,Amar,Manfred Schmidt,Ahmed Bahaaulddin A.Wahhab,Francis J. Pierciey,Guilhem Olivier Durand,Ren Chen,Sunita Goyal,Julie Kanter,John F. Tisdale	2021	1
15	Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy Blood ·Alexis A. Thompson,Mark C. Walters,Markus Y. Mapara,Janet L. Kwiatkowski,Lakshmanan Krishnamurti,Banu Aygün,Kimberly A. Kasow,Amar,Manfred Schmidt,Ahmed Bahaaulddin A.Wahhab,Francis J. Pierciey,David Alder,I.P. Ivanova,Ren Chen,Sunita Goyal,Julie Kanter,John F. Tisdale	2020	9
16	IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation Blood Advances ·Jennifer Isabel Soriano Miranda,Jing Fu,M. Bordeaux,Huihui Ma,Xiaoming Xu,Yong‐Guang Yang,Shi‐Xian Deng,Markus Y. Mapara,Suzanne Lentzsch	2018	18
17	Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies Blood ·Gurappa Puttanna Gururaj,Dale Crossman,金河龍,李达祥,Amer Assal,Markus Y. Mapara,Ran Reshef	2017	1
18	Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma Molecular Cancer Therapeutics ·Shirong Li,Jing Fu,Caisheng Lu,Markus Y. Mapara,Shahzad Raza,Ulrich Hengst,Suzanne Lentzsch	2016	20
19	Targeting the Microtubular Network as a New Antimyeloma Strategy Molecular Cancer Therapeutics ·Rentian Feng,Shirong Li,Caisheng Lu,Vera Iurevna Bedina,Donna B. Stolz,Markus Y. Mapara,Suzanne Lentzsch	2011	23
20	Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. MDC Repository (Max-Delbrueck-Center for Molecular Medicine) ·Stephan Mathas,Anke Rickers,Kurt Bommert,Bernd Dörken,Markus Y. Mapara	2000	127

About Markus Y. Mapara

Markus Y. Mapara is a scholar working on Hematology, Genetics, Immunology, Oncology and Molecular Biology, having authored 174 papers that have together received 5.0k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (49 papers), Hemoglobinopathies and Related Disorders (28 papers), Hematopoietic Stem Cell Transplantation (27 papers), Immune Cell Function and Interaction (20 papers), Prenatal Screening and Diagnostics (18 papers), T-cell and B-cell Immunology (18 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (17 papers) and Protein Degradation and Inhibitors (17 papers). The work is most often cited by research in Hematology (1.5k citations), Immunology (1.6k citations), Oncology (1.8k citations), Genetics (548 citations) and Cancer Research (649 citations). Markus Y. Mapara has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Bernd Dörken, Ralf C. Bargou, Kurt Bommert, Megan Sykes, Suzanne Lentzsch, Christian Wagener, Hans‐Dieter Royer, Peter T. Daniel, Yong‐Mi Kim and Edgar Grinstein. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, European Journal of Immunology, Journal of Clinical Investigation and Transplantation and Cellular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact